Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Cancer Rep (Hoboken). 2023 Mar;6(3):e1759. doi: 10.1002/cnr2.1759. Epub 2022 Dec 19.
Esophageal cancer (EC) is the sixth leading cause of cancer-related death, despite many advances in treatment, the survival of patients still remains poor. In recent years, the N6-methyladenosine (m6A) has been introduced as one of the most important modifications at the epitranscriptome level, with an important role in the mRNA regulation in various diseases, such as cancers. The m6A is regulated by different factors, including FTO as a demethylase. The m6A modification, especially through FTO overexpression has an oncogenic role in different cancer types such as EC. Recent studies showed that entacapone, a catechol-o-methyl transferase (COMT) inhibitor currently applied for Parkinson's disease, can inhibit FTO enzyme.
In this study, we aimed to investigate the effect of entacapone as an FTO inhibitor on the m6A level and also apoptosis and cell cycle response in KYSE-30 and YM-1 of esophageal squamous cancer cell (ESCC) lines.
Cell toxicity and IC50 of entacapone were evaluated using The MTT assay in YM-1 and KYSE-30 cells. Cells were treated into two groups: DMSO (control) and entacapone (mean IC ). Total RNA was extracted, and m6A levels were measured via the ELISA method. Subsequently, the apoptosis and cell cycle dys-regulation were detected by annexin-V-FITC/PI staining and PI staining via flow cytometry.
Entacapone has the cytotoxicity effect on both esophageal cancer cell lines compared to normal PBMC cells. As well, entacapone treatment (140 μM) can induce apoptosis (KYSE-30: 50%. YM-1:22.6%) and has a modulatory effect on cell cycle progression in both YM-1 and KYSE-30 cells (p-value<.05). However, no significant difference in the m6A concentration was observed.
Our findings suggested that entacapone has the inhibitory effect on ESCC cell lines through induction of the apoptosis and modulation of the cell cycle without toxicity on the normal PBMC.
食管癌(EC)是癌症相关死亡的第六大主要原因,尽管在治疗方面取得了许多进展,但患者的生存率仍然较差。近年来,N6-甲基腺苷(m6A)被认为是转录后组中最重要的修饰之一,在各种疾病(如癌症)的 mRNA 调控中发挥着重要作用。m6A 受不同因素的调节,包括 FTO 作为去甲基酶。m6A 修饰,特别是通过 FTO 过表达,在不同类型的癌症中具有致癌作用,如 EC。最近的研究表明,恩他卡朋是一种目前用于治疗帕金森病的儿茶酚-O-甲基转移酶(COMT)抑制剂,可以抑制 FTO 酶。
本研究旨在探讨恩他卡朋作为 FTO 抑制剂对食管鳞状癌细胞(ESCC)系 KYSE-30 和 YM-1 中 m6A 水平以及细胞凋亡和细胞周期反应的影响。
采用 MTT 法检测恩他卡朋对 YM-1 和 KYSE-30 细胞的细胞毒性和 IC50。将细胞分为两组:DMSO(对照组)和恩他卡朋(平均 IC)。提取总 RNA,通过 ELISA 法测量 m6A 水平。随后,通过 Annexin-V-FITC/PI 染色和 PI 染色通过流式细胞术检测细胞凋亡和细胞周期失调。
与正常 PBMC 细胞相比,恩他卡朋对两种食管癌细胞系均具有细胞毒性作用。此外,恩他卡朋(140 μM)处理可诱导细胞凋亡(KYSE-30:50%。YM-1:22.6%),并对 YM-1 和 KYSE-30 细胞的细胞周期进程产生调节作用(p 值<.05)。然而,m6A 浓度没有明显差异。
我们的研究结果表明,恩他卡朋通过诱导细胞凋亡和调节细胞周期对 ESCC 细胞系具有抑制作用,对正常 PBMC 无毒性。